Ibrutinib and Rituxan for Chronic GVHD

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

December 23, 2022

Study Completion Date

December 23, 2022

Conditions
Graft Vs Host Disease
Interventions
DRUG

Rituximab

Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).

DRUG

Ibrutinib

Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.

Trial Locations (1)

30342

Northside Hospital, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Northside Hospital, Inc.

OTHER